Allouchery, M.; Beuvon, C.; Pérault-Pochat, M.-C.; Roblot, P.; Puyade, M.; Martin, M.
Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review. Cancers 2022, 14, 955.
https://doi.org/10.3390/cancers14040955
AMA Style
Allouchery M, Beuvon C, Pérault-Pochat M-C, Roblot P, Puyade M, Martin M.
Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review. Cancers. 2022; 14(4):955.
https://doi.org/10.3390/cancers14040955
Chicago/Turabian Style
Allouchery, Marion, Clément Beuvon, Marie-Christine Pérault-Pochat, Pascal Roblot, Mathieu Puyade, and Mickaël Martin.
2022. "Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review" Cancers 14, no. 4: 955.
https://doi.org/10.3390/cancers14040955
APA Style
Allouchery, M., Beuvon, C., Pérault-Pochat, M.-C., Roblot, P., Puyade, M., & Martin, M.
(2022). Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review. Cancers, 14(4), 955.
https://doi.org/10.3390/cancers14040955